Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical tria...
Leadership
Benjamin J. Zeskind M.B.A., Ph.D.Founder
Co-Founder, President, CEO & Director
Robert J. Carpenter M.B.A., M.S.Founder
Co-Founder & Chair Emeritus
Brett M. Hall Ph.D.
Chief Scientific Officer
Michael D. Bookman J.D.
Chief Legal Officer & Secretary
Mallory Morales CPA
Senior VP of Finance, Chief Accounting Officer & Treasurer
Paula George CPA
Director of Accounting & Operations and Assistant Corporate Controller
Courtney Dugan
VP and Head of Investor Relations & Corporate Communications
